Show
Sort by
-
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis
-
The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications
-
Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity : biologic and clinical implications in autoimmune arthritis
-
S100A12-expression is upregulated by TNF and may serve as a marker for the success of anti-TNF therapy
-
Functional haplotypes of PAD14: Relevance for rheumatoid arthritis-specific synovial intracellular citruillinated proteins and anti-citrullinated protein antibodies
-
Tumor necrosis factor a blockade treatment down-modulates the increased systemic and local expression of toll-like receptor 2 and toll-like receptor 4 in spondylarthropathy
-
Short and long term synovial immunumodulation by etanercept in spondyloarthropathy
-
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis
-
Effective immunomodulation of peripheral joint pathology in spondyloarthropathy by etanercept
-
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies
-
Mannose-binding lectin (MBL2) polymorphisms in rheumatoid arthritis (RA) are not associated with susceptibility or radiological progression rate
-
Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase are pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity
-
Juvenile chronic arthritis displays synovial features distinct from both spondyloarthropathy and rheumatoid arthritis
-
Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity
-
Mannose-binding lectin (Mbl2) polymorphisms in rheumatoid arthritis are not associated with susceptibility, radiological progression rate, or serological markers